Patents by Inventor Fred Hofmann
Fred Hofmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952601Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect.Type: GrantFiled: June 20, 2017Date of Patent: April 9, 2024Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Patent number: 11357821Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: GrantFiled: December 9, 2019Date of Patent: June 14, 2022Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Juergen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
-
Publication number: 20220010294Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: ApplicationFiled: September 23, 2021Publication date: January 13, 2022Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Patent number: 11155802Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: GrantFiled: July 6, 2017Date of Patent: October 26, 2021Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen Frevert, Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps
-
Patent number: 11078472Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise (i) at least two random coil domains, or (ii) at least two domains having a polyproline II helix conformation, and the methods comprise the steps of inserting at least two nucleic acid sequences each coding for (i) a random coil domain, or (ii) a domain having a polyproline II helix conformation, into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising (i) the random coil domain-coding sequences, or (ii) the sequences encoding the domains having a polyproline II helix conformation in a host cell.Type: GrantFiled: January 19, 2017Date of Patent: August 3, 2021Assignee: Merz Pharma GmbH & Co., KGaAInventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Publication number: 20210008156Abstract: The invention relates to novel recombinant single-chain precursor botulinum neurotoxins serotype A comprising at least one additional domain and least one amino acid modification of the heavy chain of the neurotoxin. The novel recombinant single-chain precursor botulinum neurotoxins further comprises at least one cleavage site for a protease selected from the group consisting of thrombin, HRV3C, Tobacco Etch Vims protease, enterokinase and factor Xa. The invention further relates to novel recombinant botulinum neurotoxins serotype A exhibiting an increased duration of effect.Type: ApplicationFiled: October 26, 2017Publication date: January 14, 2021Inventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Publication number: 20200354706Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise at least one domain wherein said domain comprises an amino acid sequence consisting of at least 50 amino acid residues, wherein said amino acid sequence consists of at least one proline and at least one alanine residue. The invention relates also to novel recombinant clostridial neurotoxins comprising at least one domain wherein said domain comprises an amino acid sequence consisting of at least 50 amino acid residues, wherein said domain comprises a plurality of specific amino acid repeats consisting of proline, alanine and tyrosine residues, or proline, alanine and glutamine residues, or proline, alanine and threonine residues.Type: ApplicationFiled: November 22, 2017Publication date: November 12, 2020Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Publication number: 20200129587Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: ApplicationFiled: December 9, 2019Publication date: April 30, 2020Inventors: Juergen FREVERT, Fred HOFMANN, Michael SCHMIDT, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Publication number: 20200131494Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: ApplicationFiled: July 6, 2017Publication date: April 30, 2020Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Patent number: 10603353Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: GrantFiled: June 10, 2016Date of Patent: March 31, 2020Assignee: Merz Pharma GmbH & Co. KGaAInventors: Jürgen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
-
Publication number: 20200048624Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect.Type: ApplicationFiled: June 20, 2017Publication date: February 13, 2020Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS, Jürgen FREVERT
-
Publication number: 20180327730Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise (i) at least two random coil domains, or (ii) at least two domains having a polyproline II helix conformation, and the methods comprise the steps of inserting at least two nucleic acid sequences each coding for (i) a random coil domain, or (ii) a domain having a polyproline II helix conformation, into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising (i) the random coil domain-coding sequences, or (ii) the sequences encoding the domains having a polyproline II helix conformation in a host cell.Type: ApplicationFiled: January 19, 2017Publication date: November 15, 2018Inventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Publication number: 20180169182Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: ApplicationFiled: June 10, 2016Publication date: June 21, 2018Inventors: Jürgen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
-
Patent number: 9975929Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: GrantFiled: March 4, 2015Date of Patent: May 22, 2018Assignee: MERZ PHARMA GmbH & CO. KGaAInventors: Jürgen Frevert, Fred Hofmann, Michael Schmidt
-
Patent number: 9827298Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at feast one degradation signal in the light chain as well as vectors and host calls comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: GrantFiled: November 3, 2016Date of Patent: November 28, 2017Assignee: MERZ PHARMA GmbH & CO. KGaAInventors: Fred Hofmann, Jürgen Frevert
-
Patent number: 9809809Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises at least one E3 ligase recognition motif in the light chain, wherein said E3 ligase recognition motif is preferably a binding motif for the E3 ligase MDM2. The invention further pertains to polypeptides encoded by the polynucleotide of the invention as well as polypeptides comprising one or more amino acid substitutions. Further encompassed by the present invention are vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: GrantFiled: November 8, 2012Date of Patent: November 7, 2017Assignee: MERZ PHARMA GmbH & CO. KGaAInventors: Michael Schmidt, Jurgen Frevert, Fred Hofmann, Gerhard Groer
-
Patent number: 9688152Abstract: Advances in robot performance have been limited by a lack of advances in the mature field of battery technology. The focus of robotic power systems must expand from the use of single energy devices to the inclusion of multiple devices which can be optimized for a robotic platform. The challenge lies in the development of the hardware and control algorithms for a scalable power delivery architecture which satisfies the power and energy requirements of most unmanned ground vehicles. This invention is directed to an architecture which is easily scalable and facilitates the use of a wide variety of energy storage/generation devices, while focusing on the system control algorithm and its stability. The experimental results for an example system are presented demonstrating that the architecture functions properly when faced with real world robotic power demands.Type: GrantFiled: July 20, 2012Date of Patent: June 27, 2017Assignee: The Penn State Research FoundationInventors: Karl Martin Reichard, Christopher Mark Rogan, Elisha M. Hughes, Nathaniel John Hobbs, Heath Fred Hofmann
-
Publication number: 20170072030Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at feast one degradation signal in the light chain as well as vectors and host calls comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: ApplicationFiled: November 3, 2016Publication date: March 16, 2017Inventors: Fred HOFMANN, Jürgen Frevert
-
Publication number: 20170058006Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: ApplicationFiled: March 4, 2015Publication date: March 2, 2017Inventors: Jürgen FREVERT, Fred HOFMANN, Michael SCHMIDT
-
Patent number: 9511114Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: GrantFiled: October 19, 2015Date of Patent: December 6, 2016Assignee: MERZ PHARMA GmbH & CO. KGaAInventors: Fred Hofmann, Jurgen Frevert